Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion
By Ben Glickman
Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, giving the pharmaceutical giant access to Alpine's potential treatment for chronic kidney disease.
The companies said on Wednesday that Vertex would pay $65 a share for Alpine. Net of expected cash acquired, the deal is valued at around $4.6 billion.
Alpine Immune's lead candidate is being evaluated as a potential treatment for IgA nephropathy, a chronic kidney condition that can lead to end-stage-renal disease, and affects about 130,000 people in the U.S. The molecule, called povetacicept, is expected to enter Phase 3 development in the second half of this year, the companies said.
The acquisition is expected to close in the second quarter of 2024.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 10, 2024 16:30 ET (20:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
US Stock Market Outlook & Valuation for May 2024
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett